Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 17/20 | 1.00 |
| ▸ | CTSL | P07711 | 15/20 | 1.00 |
| ▸ | CTSB | P07858 | 14/20 | 1.00 |
| ▸ | CTSK | P43235 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5506774 | 1.00 | CTSS (1.00) | CTSSCTSLCTSBCTSK | |
| SCHEMBL1273010 | 0.96 | CTSS (0.93) | CTSSCTSLCTSBCTSK | |
| SCHEMBL1271557 | 0.96 | CTSS (0.93) | CTSSCTSLCTSBCTSK | |
| SCHEMBL1273011 | 0.96 | CTSS (0.93) | CTSSCTSLCTSBCTSK | |
| SCHEMBL1272813 | 0.94 | CTSS (0.88) | CTSSCTSLCTSBCTSK | |
| SCHEMBL14324339 | 0.94 | CTSS (0.88) | CTSSCTSLCTSBCTSK | |
| SCHEMBL1272500 | 0.94 | CTSS (0.88) | CTSSCTSLCTSBCTSK | |
| SCHEMBL2395979 | 0.93 | CTSS (0.87) | CTSSCTSLCTSBCTSK | |
| SCHEMBL2395980 | 0.93 | CTSS (0.87) | CTSSCTSLCTSBCTSK | |
| SCHEMBL1271692 | 0.92 | CTSS (0.85) | CTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663958-B1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2015-02-25 | — | — | EP | claimed |
| US-7547701-B2 | Haloalkyl containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-06-16 | — | — | US | claimed |
| JP-2007505920-A | — | — | 2007-03-15 | — | — | JP | claimed |
| EP-1663958-A2 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050182096-A1 | Haloalkyl containing compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-18 | — | — | US | claimed |
| WO-2005028429-A2 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | claimed |
| EP-1663958-B1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-1663958-B1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2012174552-A2 | CATHEPSIN INHIBITORS FOR TREATING MICROGLIA-MEDIATED NEURON LOSS IN THE CENTRAL NERVOUS SYSTEM | VIROBAY, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2010148488-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES | MERCK FROSST CANADA LTD. (CA) | 2010-12-29 | — | — | WO | disclosed |
| US-7737300-B2 | Processes and intermediates preparing cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737300-B2 | Processes and intermediates preparing cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737300-B2 | Processes and intermediates preparing cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1797032-A1 | POLYMORPHS OF THE CYSTEINE PROTEASE INHIBITOR N-(1-CYANOCYCLOPROPYL)-3-CYCLOPROPYLMETHANESULFONYL-2(R)-[2,2,2-TRIFLUORO-1(S)-(4-FLUOROPHENYL)ETHYLAMINO]PROPIONAMIDE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006034004-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034006-A1 | POLYMORPHS OF THE CYSTEINE PROTEASE INHIBITOR N- (1-CYANOCYCLOPROPYL)-3-CYCLOPROPYLMETHANSULFONYL-2 (R) - (2,2,2-TRIFLUORO-1 (S) - (4-FLUOROPHENYL) ETHYLAMINO) PROPIONAMIDE | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034006-A1 | POLYMORPHS OF THE CYSTEINE PROTEASE INHIBITOR N- (1-CYANOCYCLOPROPYL)-3-CYCLOPROPYLMETHANSULFONYL-2 (R) - (2,2,2-TRIFLUORO-1 (S) - (4-FLUOROPHENYL) ETHYLAMINO) PROPIONAMIDE | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034006-A1 | POLYMORPHS OF THE CYSTEINE PROTEASE INHIBITOR N- (1-CYANOCYCLOPROPYL)-3-CYCLOPROPYLMETHANSULFONYL-2 (R) - (2,2,2-TRIFLUORO-1 (S) - (4-FLUOROPHENYL) ETHYLAMINO) PROPIONAMIDE | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | WO | disclosed |
| US-20050182096-A1 | Haloalkyl containing compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005028429-A2 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182096-A1 | Haloalkyl containing compounds as cysteine protease inhibitors | CTSF, CTSS, CTSE | CTSS 2/4885CTSL 9/4885CTSB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.